C3N-01419
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 58.65023956
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.570
- MYC_TARGETS_V1+0.460
- OXIDATIVE_PHOSPHORYLATION+0.440
- GLYCOLYSIS+0.380
- E2F_TARGETS+0.370
- ADIPOGENESIS+0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.330
- P53_PATHWAY+0.320
- INTERFERON_ALPHA_RESPONSE+0.310
- DNA_REPAIR+0.290
Top 10 suppressed
- UV_RESPONSE_DN-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- HEDGEHOG_SIGNALING-0.340
- TGF_BETA_SIGNALING-0.320
- ANGIOGENESIS-0.290
- INFLAMMATORY_RESPONSE-0.250
- APICAL_SURFACE-0.230
- ANDROGEN_RESPONSE-0.220
- IL2_STAT5_SIGNALING-0.210
- PROTEIN_SECRETION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG713 | — | — | 0.843 |
| 2 | 8c76ce45-f110-4f6a-b413-13a1a1aeddef | — | — | 0.836 |
| 3 | 2d83a9e6-da2d-47e1-b2e7-4b07b108f7bd | — | — | 0.827 |
| 4 | TCGA-62-A471-01A-12R-A24H-07 | — | cohortA4 | 0.821 |
| 5 | 48128da3-329b-45c5-be65-c8cbeccddb97 | — | — | 0.813 |
| 6 | SRR25043614 | — | — | 0.805 |
| 7 | SRR8526731 | — | cohortA4 | 0.805 |
| 8 | TCGA-XF-A9T6-01A-11R-A42T-07 | — | — | 0.804 |
| 9 | TCGA-39-5036-01A-01R-1443-07 | — | cohortSQ2 | 0.803 |
| 10 | cdef9a7f-9daa-4a33-b196-08a12a2ed203 | — | — | 0.803 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.380 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.330 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.320 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.160 | Inavolisib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |